[Experimental studies on the treatment of recurrent gliomas].
For the purpose to study reasonable treatment for recurrent gliomas, in vitro immunochemosensitivity tests were performed by using human malignant glioma cell line (ONS-12) and its ACNU-resistant cell line (ONS-12/ACNU), which were established in our laboratory. ONS-12/ACNU cells showed a cross-resistance to Ara-C, but not for cisplatin and methotrexate. The lymphokine-activated killer (LAK) cells induced in vitro from the peripheral blood lymphocytes (PBL) of healthy subjects, showed stronger cytotoxicity to ONS-12/ACNU than ONS-12 cells. From these data, selection of appropriate anti-tumor agents on the in vitro sensitivity tests was a most useful method for the treatment of recurrent gliomas, and the adoptive immunotherapy with LAK cells may be useful for ACNU-resistant gliomas.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D002460:Cell Line; D002478:Cells, Cultured; D004351:Drug Resistance; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000637:transplantation*; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000494:pharmacology*
D000970:Antineoplastic Agents; D007376:Interleukin-2; D009607:Nitrosourea Compounds; D015376:Nimustine